详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

The association of blood ctDNA levels to mutations of marker genes in colorectal cancer

56| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ ESCI

作者：

机构： [1]Hunan Cancer Hospital and The Affiliated cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China. [2]School of Biological Sciences, University of Nebraska, Lincoln, Nebraska, USA. [3]Chengdu Medical College, Chengdu, Sichuan, China. [4]Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, China. [5]Department of oncology, Chengdu Ping-An Hospital, Chengdu, Sichuan, China. [6]Chengdu Women and Children's Center Hospital, Chengdu, Sichuan, China.

出处：

DOI：

摘要：

Colorectal cancer (CRC) is a deadly and commonly diagnosed cancer. Cell-free circulating tumor DNAs (ctDNA) have been used in the diagnosis and treatment of CRC, but there are open questions about the relationship between ctDNAs and CRC. Although mutations of genes detected by ctDNA in CRC have been studied, the quantitative relationship between ctDNA mutations and ctDNA concentration has not been addressed.We hypothesized that there was an association between mutations of genes identified in ctDNAs and ctDNA concentration. His study examined this association in a population of CRC patients.In 85 CRC patients, we sampled 282 mutations in 36 genes and conducted an association study based on a Random forest model between mutations and ctDNA concentrations in all patients.This association study showed that mutations on five genes, ALK, PMS2, KDR, MAP2K1, and MSH2, were associated with the ctDNA concentrations in CRC patients' blood samples. Because ctDNA mutations correlate with ctDNA level, we can infer the tumor burden or tumor size from ctDNA mutations, as well as the survival time for prognosis.Our findings shed light on the associations between mutations of genes identified in ctDNAs and ctDNA concentration in the blood of CRC patients. This discovery provides information regarding the tumor burden or tumor size based on ctDNA mutations.© 2023 The Authors. Cancer Reports published by Wiley Periodicals LLC.

基金：

语种：

WOS：

PubmedID：

JCR分区：

出版当年[2023]版：

Q4 ONCOLOGY

最新[2023]版：

Q4 ONCOLOGY

影响因子： 1.5 最新[2023版] 1.6 最新五年平均 1.5 出版当年[2023版] 1.6 出版当年五年平均 1.7 出版前一年[2022版]

第一作者：

第一作者机构： [1]Hunan Cancer Hospital and The Affiliated cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.

共同第一作者：

通讯作者：

通讯机构： [1]Hunan Cancer Hospital and The Affiliated cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China. [2]School of Biological Sciences, University of Nebraska, Lincoln, Nebraska, USA. [3]Chengdu Medical College, Chengdu, Sichuan, China. [*1]Chengdu Medical College, Chengdu, Sichuan, China. [*2]School of Biological Sciences, University of Nebraska, Lincoln, NE, USA. [*3]Hunan Cancer Hospital, and the Affiliated Cancer Hospital of the Xiangya School of Medicine, Central South University, Changsha, China.

推荐引用方式(GB/T 7714)：

APA：

MLA：